Stocks · News reference
Halozyme Therapeutics Reports Q3 2026 Financial Results and Raises Full-Year Guidance
Halozyme Therapeutics reported strong third-quarter 2026 financial results, featuring a 39% year-over-year revenue increase and an upward revision to its full-year 2026 financial outlook.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Wells Fargo Maintains Equal-Weight on Halozyme Therapeutics, Raises Price Target to $110
FDA Grants Accelerated Approval to RYBREVANT FASPRO™ for Head and Neck Squamous Cell Carcinoma
The FDA has granted accelerated approval to RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj), which utilizes Halozyme's ENHANZE® drug delivery technology, for the treatment of head and neck squamous cell carcinoma.
JP Morgan Maintains Neutral Rating and Raises Price Target for Halozyme Therapeutics
JP Morgan has maintained its 'Neutral' rating on Halozyme Therapeutics while increasing the price target from $78 to $79.
Clinical Data Presentation for RYBREVANT FASPRO Utilizing Halozyme's ENHANZE Technology
Recent clinical data presented at the ESMO Congress 2026 highlights the efficacy of subcutaneous amivantamab, which utilizes Halozyme's ENHANZE drug delivery technology.
Halo Minerals PLC Receives Key Mining Permit for Playa Verde Project
Halo Minerals PLC's subsidiary, Minera Playa Verde SpA, has been granted a critical mining permit for its copper and gold tailings project in Chile.